BR9505039A - Derivados de oxazolidinona enantiômeros ou diastereômeros dos compostos processo para sua preparação processo para a produção de uma preparação farmacêutica e uso - Google Patents

Derivados de oxazolidinona enantiômeros ou diastereômeros dos compostos processo para sua preparação processo para a produção de uma preparação farmacêutica e uso

Info

Publication number
BR9505039A
BR9505039A BR9505039A BR9505039A BR9505039A BR 9505039 A BR9505039 A BR 9505039A BR 9505039 A BR9505039 A BR 9505039A BR 9505039 A BR9505039 A BR 9505039A BR 9505039 A BR9505039 A BR 9505039A
Authority
BR
Brazil
Prior art keywords
diastereomers
preparation
production
oxazolidinone derivatives
compounds
Prior art date
Application number
BR9505039A
Other languages
English (en)
Inventor
Joachim Gante
Horst Juraszyk
Peter Raddatz
Hanns Wurziger
Sabine Bernotat-Danielowski
Guido Melzer
Matthias Wiesner
Claus Fittschen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19509093A external-priority patent/DE19509093A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9505039A publication Critical patent/BR9505039A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
BR9505039A 1994-11-02 1995-11-01 Derivados de oxazolidinona enantiômeros ou diastereômeros dos compostos processo para sua preparação processo para a produção de uma preparação farmacêutica e uso BR9505039A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4439110 1994-11-02
DE19509093A DE19509093A1 (de) 1994-11-02 1995-03-16 Adhäsionsrezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
BR9505039A true BR9505039A (pt) 1997-10-21

Family

ID=25941621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9505039A BR9505039A (pt) 1994-11-02 1995-11-01 Derivados de oxazolidinona enantiômeros ou diastereômeros dos compostos processo para sua preparação processo para a produção de uma preparação farmacêutica e uso

Country Status (19)

Country Link
US (2) US6602876B1 (pt)
EP (1) EP0710657B1 (pt)
JP (1) JP3810837B2 (pt)
CN (1) CN1067384C (pt)
AT (1) ATE170179T1 (pt)
AU (1) AU698987B2 (pt)
BR (1) BR9505039A (pt)
CA (1) CA2161857C (pt)
CZ (1) CZ290658B6 (pt)
DK (1) DK0710657T3 (pt)
ES (1) ES2123889T3 (pt)
FI (1) FI955223A (pt)
HU (1) HU217437B (pt)
MX (1) MX9504630A (pt)
NO (1) NO305246B1 (pt)
PL (1) PL182291B1 (pt)
RU (1) RU2165928C2 (pt)
SK (1) SK282123B6 (pt)
TR (1) TR199501359A2 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
IL125756A (en) 1996-02-15 2003-05-29 Biosense Inc Catheter for use in surgery
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
EP0917878A4 (en) * 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
DE19755268A1 (de) * 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US6555562B1 (en) 1998-02-26 2003-04-29 Celltech R&D Limited Phenylalanine derivatives
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
BR9910971A (pt) 1998-06-05 2001-02-13 Astrazeneca Ab Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
KR20010109275A (ko) 1998-12-23 2001-12-08 로저 에이. 윌리암스 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
AU4112900A (en) 1999-04-13 2000-11-14 Basf Aktiengesellschaft Integrin receptor ligands
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
AU2001253113B2 (en) * 2000-04-20 2005-02-03 Pharmacia & Upjohn Company Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
DE10108995A1 (de) * 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
CN105820160B (zh) * 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
KR101224368B1 (ko) 2004-06-04 2013-01-22 더 스크립스 리서치 인스티튜트 혈관신생 질환 치료용 조성물 및 방법
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
JP2009516730A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−アラニン誘導体
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB834968A (en) * 1957-08-28 1960-05-18 Robins Co Inc A H 5-o-alkoxyphenoxymethyl-2-oxazolidones
DE3205457A1 (de) * 1982-02-16 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Oxazolidin-2-one
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
FR2675504B1 (fr) * 1991-04-16 1995-01-27 Delalande Sa Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
US5480899A (en) * 1992-04-30 1996-01-02 Taiho Pharmaceutical Co., Ltd. Oxazolidine derivatives and pharmaceutically acceptable salts thereof
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten

Also Published As

Publication number Publication date
EP0710657B1 (de) 1998-08-26
CA2161857A1 (en) 1996-05-03
FI955223A0 (fi) 1995-11-01
SK282123B6 (sk) 2001-11-06
HU217437B (hu) 2000-01-28
NO954366L (no) 1996-05-03
CA2161857C (en) 2007-10-09
AU698987B2 (en) 1998-11-12
PL182291B1 (pl) 2001-12-31
US6602876B1 (en) 2003-08-05
TR199501359A2 (tr) 1996-06-21
CZ290658B6 (cs) 2002-09-11
RU2165928C2 (ru) 2001-04-27
JPH08225550A (ja) 1996-09-03
CZ285895A3 (en) 1996-05-15
JP3810837B2 (ja) 2006-08-16
PL311194A1 (en) 1996-05-13
CN1130626A (zh) 1996-09-11
FI955223A (fi) 1996-05-03
SK135895A3 (en) 1996-06-05
MX9504630A (es) 1997-01-31
ATE170179T1 (de) 1998-09-15
HU9503131D0 (en) 1995-12-28
DK0710657T3 (da) 1999-05-25
AU3452395A (en) 1996-05-09
NO954366D0 (no) 1995-11-01
ES2123889T3 (es) 1999-01-16
CN1067384C (zh) 2001-06-20
EP0710657A1 (de) 1996-05-08
HUT74093A (en) 1996-11-28
NO305246B1 (no) 1999-04-26
US6204280B1 (en) 2001-03-20

Similar Documents

Publication Publication Date Title
BR9505039A (pt) Derivados de oxazolidinona enantiômeros ou diastereômeros dos compostos processo para sua preparação processo para a produção de uma preparação farmacêutica e uso
FI955024A0 (fi) Uudet piperidiiniyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
NO952482D0 (no) Peptider av borsyre, samt fremstilling derav
BR9504379A (pt) Derivados de amino(thio)éter enantiômero processo para a preparaçao de um composto processo para a preparaçao de preparados farmacêuticos preparados farmacêuticos e uso
PT95202A (pt) Processo para a preparacao de n-substituidas-4-pirimidinaminas e de composicoes farmaceuticas que os contem
FI885332A0 (fi) 3-/4- (-1-substituerad-4-piperazinyl) butyl/-4-tiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
PT82480B (pt) Processo para a preparacao de 2-amino tiazois n- substituidos e das correspondentes composicoes farmaceuticas
PT90022A (pt) Processo para a preparacao de derivados cefem e dos intermediarios correspondentes
BR9503817A (pt) Derivados de ácido benzóico orto-substituídos processo para sua preparação processo para a produção de uma preparação farmacêutica preparação farmacêutica e uso
FI920435A0 (fi) N-(aryloxyalkyl) heteroaryl-8 -azabicyclo/3.2.1./oktaner, mellanprodukter och deras framstaellnings -foerfarande och deras anvaendning som laekemedel.
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
ES2115722T3 (es) Compuestos de benzaldehido anticancerosos.
IT1213555B (it) 2 metiltiometildiidropiridine, un processo per laloro preparazione e composizioni farmaceutiche che le contengono.
HU9602331D0 (en) Alkenyl-benzoyl-guanidine derivatives
DE69608983D1 (de) Thiophenverbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen
NO953320D0 (no) Cykloheksanderivater
GB8823041D0 (en) Organic compounds & their use as pharmaceuticals

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 12A , 13A E 14A ANUIDADES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2049 DE 13/04/2010 E COMPROVAR RECOLHIMENTO DA 15A , 16A , 17A E 18A ANUIDADES.